Suppressed bone turnover by long-term bisphosphonate treatment accumulates microdamage by maintains intrinsic material properties in cortical bone of dog rib (reprinted vol 19, pg 999, 2004)

被引:2
作者
Komatsubara, S
Mori, S [1 ]
Mashiba, T
Li, JL
Nonaka, K
Kaji, Y
Akiyama, T
Miyamoto, K
Cao, YP
Kawanishi, J
Norimatsu, H
机构
[1] Kagawa Univ, Fac Med, Dept Orthoped Surg, Kagawa 7610793, Japan
[2] Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46204 USA
[3] Tokyo Med Dent Univ, Div Biomatrix, Dept Hard Tissue Engn, Pharmacol Sect, Tokyo, Japan
关键词
microdamage; bone remodeling; bisphosphonate; histomorphometry; BMD;
D O I
10.1359/jbmr.2005.20.11.2066
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Recently, we have reported that long-term suppression of bone remodeling increases microdamage accumulation but is not necessarily associated with vertebral fragility because of compensated increase of bone mass and improved microarchitecture. This study aimed to investigate the effect of long-term suppression of bone remodeling by bisphosphonate on the degree of mineralization, accumulation of microdamage, and mechanical properties of cortical bone in the same dogs. Materials and Methods: Twenty-nine 1-year-old beagles (15 males, 14 females) were divided into three groups and treated daily with vehicle (CNT) or with incadronate at a dose of 0.3 (LOW) or 0.6 mg/kg/day (HIGH) orally for 3 years. After death, pQCT, histomorphometry, microdamage measurements, and three-point bending mechanical test were performed using the ninth rib. Results: Cortical BMD was increased in the incadronate-treated groups. Cortical activation frequency was suppressed by 82% and 70% in HIGH and LOW, respectively, compared with CNT, without impairment of mineralization. Microdamage accumulation was increased in both incadronate-treated groups. Although there were no significant differences in total and cortical area among the three groups, structural mechanical properties were significantly increased after incadronate treatment while intrinsic material properties were not changed in the incadronate-treated groups. Conclusion: This study suggests that long-term suppression of bone remodeling by bisphosphonate increases microdamage accumulation. However, this was not necessarily associated with a reduction of intrinsic material properties probably because of an increased degree of mineralization.
引用
收藏
页码:2066 / 2073
页数:8
相关论文
共 31 条
[1]   Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].
Black, DM ;
Cummings, SR ;
Karpf, DB ;
Cauley, JA ;
Thompson, DE ;
Nevitt, MC ;
Bauer, DC ;
Genant, HK ;
Haskell, WL ;
Marcus, R ;
Ott, SM ;
Torner, JC ;
Quandt, SA ;
Reiss, TF ;
Ensrud, KE .
LANCET, 1996, 348 (9041) :1535-1541
[2]   Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women [J].
Boivin, GY ;
Chavassieux, PM ;
Santora, AC ;
Yates, J ;
Meunier, PJ .
BONE, 2000, 27 (05) :687-694
[3]   ALTERATIONS TO THE EN-BLOC BASIC FUCHSIN STAINING PROTOCOL FOR THE DEMONSTRATION OF MICRODAMAGE PRODUCED IN-VIVO [J].
BURR, DB ;
HOOSER, M .
BONE, 1995, 17 (04) :431-433
[4]   Bone microdamage acid skeletal fragility in osteoporotic and stress fractures [J].
Burr, DB ;
Forwood, MR ;
Fyhrie, DP ;
Martin, B ;
Schaffler, MB ;
Turner, CH .
JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 (01) :6-15
[5]   VALIDITY OF THE BULK-STAINING TECHNIQUE TO SEPARATE ARTIFACTUAL FROM INVIVO BONE MICRODAMAGE [J].
BURR, DB ;
STAFFORD, T .
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 1990, (260) :305-308
[6]   Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis [J].
Chavassieux, PM ;
Arlot, ME ;
Reda, C ;
Wei, L ;
Yates, AJ ;
Meunier, PJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (06) :1475-1480
[7]   Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial [J].
Cummings, SR ;
Black, DM ;
Thompson, DE ;
Applegate, WB ;
Barrett-Connor, E ;
Musliner, TA ;
Palermo, L ;
Prineas, R ;
Rubin, SM ;
Scott, JC ;
Vogt, T ;
Wallace, R ;
Yates, AJ ;
LaCroix, AZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (24) :2077-2082
[8]   Treatment with alendronate prevents fractures in women at highest risk - Results from the fracture intervention trial [J].
Ensrud, KE ;
Black, DM ;
Palermo, L ;
Bauer, DC ;
BarrettConnor, E ;
Quandt, SA ;
Thompson, DE ;
Karpf, DB .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (22) :2617-2624
[9]   Bisphosphonates: Preclinical aspects and use in osteoporosis [J].
Fleisch, HA .
ANNALS OF MEDICINE, 1997, 29 (01) :55-62
[10]  
FLEISH H, 2000, FROM LAB PATIENT, P56